Apollohosp FY25 Annual Earnings Summary

Bangladesh contributes ~30% of international patient revenue (2% of total revenue). Recent political issues have caused a drop in volumes, though management expects recovery.

ARPOB grew only 2% YoY due to a higher proportion of medical admissions. Management expects improvement but there is risk if surgical volumes do not pick up as anticipated.

Operationalization of four new hospitals (1,500 beds) over next five quarters could reduce EBITDA margins by 100-150bps from FY25 exit levels.

International patient revenue from Bangladesh fell 27% in H1, impacting Tamil Nadu volumes. Recovery expected but uncertain.

Quick commerce players are impacting non-Rx sales, delaying unit economics improvement. Management is rolling out 19-min delivery to counter.

1,400 new beds in FY26 could drag EBITDA margins by 1-1.2% during ramp-up, though management expects 12-14 month breakeven.

Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.

Analyst raised concerns about high ESOP costs and competition from startups; management acknowledged but defended ESOP as retention tool.

Large capacity addition (1,737 beds) could pressure margins if occupancy ramps slower than expected; management expects 100 bps margin impact.

Continued impact from reduced Bangladesh patient inflows, expected to persist through Q1 FY26, affecting hospital revenue and margins.

New hospitals in Gurgaon, Pune, Kolkata, and Hyderabad will incur initial losses, potentially compressing healthcare services margins by ~140 bps in FY26.

Health insurers facing high claims ratios may exert pressure on hospital pricing. Management believes network strength mitigates this.